| Old Articles: <Older 3741-3750 Newer> |
|---|
 |
The Motley Fool
May 24, 2007
Brian Lawler |
Learn From Northfield's Bloody Results Northfield announces clinical trial results that investors can learn from. As long as they at least give the appearance of trying to advance their compounds forward, development-stage drugmakers can go on for years always getting investor funding from somewhere.   |
The Motley Fool
May 23, 2007
Mike Havrilla |
Cypress Bioscience Comes Full Circle A potential treatment for fibromyalgia sent shares close to $17 today. |
The Motley Fool
May 23, 2007
Brian Orelli |
Pharma TV -- All Drugs, All the Time A combined media effort of four big pharmas in Europe sounds like a great idea, from an investor's perspective. But will it work? |
Pharmaceutical Executive
May 1, 2007
Diane West |
Spend Trends 2007: Hang 10 Direct-to-Consumer Advertising Hits Its First Decade: Dr. Dot-Com... Digital Detailing... etc. |
Chemistry World
May 22, 2007
Victoria Gill |
GSK Drug's Safety Questioned A prominent US clinician has concluded that a diabetes drug produced by UK pharmaceutical company GlaxoSmithKline increases the risks of heart attack and death. |
The Motley Fool
May 22, 2007
Mike Havrilla |
InSite's Vision of Profits Could InSite be looking at a surge in its value? The biotech's pipeline actually carries a very low risk, based on its proven ability to achieve FDA approval with AzaSite and the well known attributes of the drugs that are in its product formulations. |
The Motley Fool
May 22, 2007
Mike Havrilla |
An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note. |
The Motley Fool
May 22, 2007
Mike Havrilla |
Coley Gets a Cold Reception The market cares little for this drug developer's promising prospects, but some investors like this pharma at it current $230 million market cap, given the company's strong partnerships. |
The Motley Fool
May 22, 2007
Mike Havrilla |
Savient Seems Set for a Success With generic competition against one drug, the company is ready to produce another. Biotech investors are encouraged to take a look here. |
The Motley Fool
May 22, 2007
Brian Lawler |
Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing. |
| <Older 3741-3750 Newer> Return to current articles. |
